Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Perimenopausal Patients at Significant Risk For Depression Emergence
06/13/2024
Compared to those in the pre-menopause phase, perimenopausal patients are at a higher risk for depressive symptoms and diagnoses. Results from the systematic review and meta-analysis were published in The Journal of Affective...
Compared to those in the pre-menopause phase, perimenopausal patients are at a higher risk for depressive symptoms and diagnoses. Results from the systematic review and meta-analysis were published in The Journal of Affective...
Compared to those in the...
06/13/2024
Psych Congress Network
Symptom Improvement Found Across Diagnoses With Placebo
News
Symptom Improvement Found Across Diagnoses With Placebo
06/12/2024
Placebo treatment was found to improve symptoms across multiple disorders, though the level of improvement varied from diagnosis to diagnosis, according to a systematic review and meta-analysis published in JAMA Psychiatry. 
Placebo treatment was found to improve symptoms across multiple disorders, though the level of improvement varied from diagnosis to diagnosis, according to a systematic review and meta-analysis published in JAMA Psychiatry. 
Placebo treatment was found to...
06/12/2024
Psych Congress Network
four college students walking down a hall together
News
Adolescents and Young Adults Willing to Intervene During Overdose but Lack Naloxone Knowledge
06/11/2024
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of...
06/11/2024
Psych Congress Network

Advertisement

FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
News
FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
06/11/2024
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma,...
06/11/2024
Psych Congress Network
More ADHD Inattention in Young Adulthood Predicts Midlife Dissatisfaction
News
ADHD Symptoms Stable During Transition into Adulthood With Complex Impacts on Life Success
06/10/2024
Symptoms of attention-deficit/hyperactivity disorder (ADHD) are generally stable throughout the transition from emerging adulthood to early mid-adulthood, according to a study published online in the Journal of Attention Disorders.
Symptoms of attention-deficit/hyperactivity disorder (ADHD) are generally stable throughout the transition from emerging adulthood to early mid-adulthood, according to a study published online in the Journal of Attention Disorders.
Symptoms of...
06/10/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network

Advertisement

pediatric adhd
News
Several Treatments Effective in Youth With ADHD, but Evidence Strongest for Medication
05/31/2024
While treatments that improve attention-deficit/hyperactivity disorder (ADHD) in children and adolescents are diverse and growing, medications have the strongest evidence base for improved outcomes.
While treatments that improve attention-deficit/hyperactivity disorder (ADHD) in children and adolescents are diverse and growing, medications have the strongest evidence base for improved outcomes.
While treatments that improve...
05/31/2024
Psych Congress Network
Patients With Anhedonia More Severely Affected Than Other Patients With MDD
News
Patients With Anhedonia More Severely Affected Than Other Patients With MDD
05/30/2024
Patients with major depressive disorder and anhedonia may have more severe depressive symptoms than patients with MDD and no/low anhedonia (other-MDD), according to results presented via poster at Psych Congress Elevate. 
Patients with major depressive disorder and anhedonia may have more severe depressive symptoms than patients with MDD and no/low anhedonia (other-MDD), according to results presented via poster at Psych Congress Elevate. 
Patients with major depressive...
05/30/2024
Psych Congress Network
brain health
News
Rapid Procedural Approach Increases Opioid Treatment Initiation but Faces Resource Challenges
05/23/2024
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach...
05/23/2024
Psych Congress Network

Advertisement

Grief-Focused CBT May Be More Effective Than Mindfulness for Prolonged Grief Disorder
News
Grief-Focused CBT May Be More Effective Than Mindfulness for Prolonged Grief Disorder
05/23/2024
Although both grief-focused CBT and mindfulness-based cognitive therapy eased grief severity in adults with prolonged grief disorder, grief-focused CBT was associated with greater symptom reduction 6 months after treatment.
Although both grief-focused CBT and mindfulness-based cognitive therapy eased grief severity in adults with prolonged grief disorder, grief-focused CBT was associated with greater symptom reduction 6 months after treatment.
Although both grief-focused CBT...
05/23/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use